Patrick Harran joined the faculty at the University of Texas Southwestern Medical Center in 1997. In 2005, he was promoted to full Professor and named the Mar Nell & F. Andrew Bell Distinguished Chair in Biochemistry. He joined the faculty at UCLA in 2008 as the inaugural D.J. & J.M. Cram Chair in Organic Chemistry.
Harran has been a Fellow of the Alfred P Sloan Foundation, the recipient of a CAREER award from the NSF, an Eli Lilly Grantee, the AstraZenenca Excellence in Chemistry Award, the Pfizer Award for Creativity in Organic Synthesis, the Distinguished Alumni Award from Skidmore College, and the Merck Chemistry Council Award. In 2005 he was awarded the E. Bright Wilson Prize from Harvard University and named the Mar Nell and F Andrew Bell Distinguished Chair in Biochemistry at UTSW. In 2007 he received the Norman Hackerman Award in Chemical Research from the Robert A Welch Foundation.
In 2005, Dr. Harran co-founded Joyant Pharmaceuticals with the backing of Sanderling Ventures. Assets developed at Joyant provided a basis for launching Diazon Pharmaceuticals in 2013.
Dr. Harran received his Bachelors degree in chemistry from Skidmore College in New York. He holds a Ph.D. from Yale University in 1995 and completed an NIH-sponsored postdoctoral fellowship at Stanford University in 1997.
Gordon Shore was Professor of Biochemistry and Oncology and member of the Rosalind and Morris Goodman Cancer Research Center of McGill University, is internationally recognized for his research on cell survival and death mechanisms.
In 1998, he leveraged this research and co-founded Gemin X Pharmaceuticals Inc. and was a Director and its chief scientific officer until 2011 when it was acquired by Cephalon (now Teva). He was also interim CEO (2007/8). During his tenure with the company, Gemin X advanced two novel, targeted small molecule drug candidates from concept, through discovery and into late stage clinical development in oncology. He focused additional research efforts both at Gemin X and at McGill to elucidate rational paths to clinical proof of concept studies for these agents.
In 2010, Dr. Shore, together with his colleague Dr. Anne Roulston, extended such research at McGill, winning grants to build an Integrated Functional Genomics Platform that conducts genome-wide approaches focused on synthetic lethality and personalized medicine. The goal of this Integrated Platform is to generate the knowledge and tools to elucidate a clinical path forward for new targeted agents, especially in, but not limited to, oncology.
Dr. Shore obtained his Ph.D. at McGill University and pursued post-doctoral studies at the National Institute for Medical Research, London, UK.
Anne Roulston was associate director of the Laboratory for Therapeutic Development (LTD) at the Rosalind and Morris Goodman Cancer Centre of McGill University and has over 20 years’ experience in oncology drug development and research.
Since its inception, the LTD and collaborators have identified clinical strategies for three different anti-cancer agents with the aid of the Integrated Functional Genomics Platform.
Prior to the co-initiation of the LTD in 2010, Dr. Roulston was associate director of biology at Gemin X Pharmaceuticals Inc. where she led a translational research team to study the mechanism of action of Gemin X compounds and to support pre-clinical and clinical development of drug candidates.
Dr. Roulston was a post-doctoral fellow at Chiron Corporation (now Novartis) in Emeryville CA. She holds a Ph. D. from McGill University’s department of Microbiology and Immunology and has published research papers in the fields of translational cancer research, apoptosis and virology.